Leerink Partnrs Issues Negative Outlook for IRWD Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share estimate for Ironwood Pharmaceuticals from $0.13 to $0.11, aligning it closer to the consensus estimate of $0.10 for the full year.
• Various analysts have recently adjusted their ratings on Ironwood Pharmaceuticals, with Jefferies lowering its target price from $8.00 to $0.70, and Leerink Partners dropping it from $3.00 to $1.00.
• The stock has experienced significant volatility, with a 12-month high of $5.21 and a low of $0.53, reflecting investor uncertainty following recent analyst ratings and earnings adjustments.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Ironwood Pharmaceuticals in a report issued on Thursday, August 7th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.13. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.11 EPS and FY2026 earnings at $0.43 EPS.

A number of other equities research analysts have also weighed in on IRWD. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $4.94.

Ironwood Pharmaceuticals Trading Down 5.0%

Shares of IRWD stock traded down $0.06 during trading hours on Monday, reaching $1.04. 646,226 shares of the company's stock were exchanged, compared to its average volume of 2,893,134. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $5.21. The stock has a market cap of $167.48 million, a PE ratio of -20.70 and a beta of 0.33. The stock's fifty day moving average price is $0.76 and its two-hundred day moving average price is $1.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. The company had revenue of $85.24 million for the quarter, compared to analyst estimates of $62.02 million.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Large investors have recently made changes to their positions in the company. Armistice Capital LLC raised its stake in shares of Ironwood Pharmaceuticals by 44.7% during the 1st quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after buying an additional 4,232,000 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 147.6% during the 2nd quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company's stock worth $4,685,000 after purchasing an additional 3,904,498 shares during the period. Millennium Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the period. Marshall Wace LLP boosted its holdings in Ironwood Pharmaceuticals by 616.3% during the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company's stock valued at $2,875,000 after acquiring an additional 3,436,036 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock valued at $5,160,000 after acquiring an additional 3,092,475 shares during the period.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.